Itsibio News

April, 2008

Life Sciences-Ltda of Sao Paulo, Brazil appointed exclusive distributor

ITSIBIO has signed a representation and distribution agreement with Life Sciences-Ltda (http://www.life-sciences.com.br), Sao Paulo, Brazil. This agreement, which is effective from March 14th 2008, gives Life Sciences exclusive rights to promote, market and distribute ITSIBIO products in Brazil. Clients in this territory can now place orders for all products available at (http://www.itsibio.com/index_intop.htm) through Life Sciences.

March, 2008

ITSIBIO signs distribution agreement with Precision Technologies PTE Ltd, Singapore

ITSIBIO has signed a representation and distribution agreement with Precision Technologies PTE Ltd, Singapore (www.pretech.com.sg). This agreement, which is effective March 17th 2008, gives Precision Technologies exclusive rights to promote, market and distribute ITSIBIO products in Singapore, Malaysia and Indonesia. Clients in this territory can now place orders for all ITSIBIO products (http://www.itsibio.com/index_intop.htm) through Precision Technologies. Orders can be place by Phone: +6273-4573, Fax 6273-8898 or E-mail: scitech@pretech.com.sg.

February, 2008

ITSIBio Facility Update
The new ITSIBio facility is to be completed in August 2008. Included below is and updated Artist Rendering of the new facility

Larger Image

January, 2008

NCI extends Blanket Purchase Agreement with ITSIBIO to 2010.

NCI (http://web.ncifcrf.gov/about/default.asp) has extended the Blanket Purchase Agreement (BPA), originally signed with ITSIBIO in 2005, until 2010. This highly successful BPA which is managed by SAIC-Frederick (http://saic.ncifcrf.gov/company_overview.asp ), allows all NCI researchers to purchase genomics, proteomics and mass spectrometry services, and consumables from ITSIBIO at a pre-negotiated price. The BPA streamlines the process of outsourcing analytical support and locks-in lower prices for all investigators by leveraging economy of scale. Because the BPA contains legally binding confidentiality and non-disclosure clauses, researchers can fully discuss their experiments with the confidence that their ideas and scientific results will be safe and protected to the full extent required by law.

ITSIBIO receives Human Subject Research and ICH-GCP Certification.

ITSIBIO has received the “Human Subject Research” and “International Conference on Harmonization (ICH) – Good Clinical Practice (GCP)” certifications. ICH-GCP (http://www.ich.org/cache/compo/276-254-1.html) brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry to ensure protection of human subjects and allow a “more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public health”. ICH-GCP facilitates the dissemination and communication of information on harmonized guidelines, and the use such information/guidelines to encourage the implementation and integration of common standards. This significant milestone means that ITSIBIO’s staffs have a working knowledge of the principles and ethics associated with good clinical practices, understands Good Clinical Practices dictated by FDA (http://www.fda.gov/oc/gcp/regulations.html) and the ICH Requirements for Sponsors, Monitors, and Investigators. ITSIBIO affirms that all projects performed at ITSIBIO will strictly adhere to “Use of Human Subject Research” and “ICH-GCP” guidelines to allow the submission of the data for regulatory approval. Both certifications were received through the Collaborative Institution Training Initiative (CITI, http://www.citiprogram.org/).

ITSIBIO signs agreement with BioConsult, Jerusalem, Israel.

ITSIBIO has appointed BioConsult, Jerusalem, Israel (http://www.bioconsult.co.il/ ) as the exclusive distributor and representative in Israel. The agreement signed December 2007, gives BioConsult exclusive rights to promote, market and distribute all ITSIBIO products and services in Israel. Clients in Israel can now place orders through BioConsult via phone or by visiting their website. Please visit http://www.itsibio.com/index_intop.htm to see products now available to customers in Israel.

ITSIBIO signs collaboration agreement with University of the Western Cape, Bellville, South Africa.

ITSIBIO has signed a collaboration agreement with the University of Western Cape Proteomics Research Group. Under the agreement, signed December 2007, both parties will collaborate in the areas of proteomics and sample preparation reagent development.

ITSI-Biosciences signs collaboration and distribution agreement with Innovative Biotech Ltd, Keffi Nigeria.

ITSIBIO enters the Nigerian market by signing a collaboration agreement with Innovative Biotech Limited (IBL), Keffi, Nigeria (www.innovativebiotechng.com). Under the agreement signed November 2007, ITSIBIO and IBL will collaborate to develop diagnostic assays for infectious diseases of national interest to Nigeria and the West African region. A distribution agreement signed in December 2007 during the visit of Simon Agwale, PhD, IBL CEO, to ITSIBIO head office in Johnstown, PA also gives IBL the exclusive rights to market, distribute and support ITSIBIO, Panomics Inc. and GenVault Inc products and services in Nigeria. All orders in the Nigerian market should now be placed through IBL Nigeria. Please visit http://www.itsibio.com/index_intop.htm to see the products now available to customers in Nigeria through IBL.

Bin Ali Medical Supplies appointed distributor for the Middle East market.

ITSIBIO announced today the appointment of Bin Ali Medical Supplies (BAMS), Abu Dhabi, United Arab Emirates (http://www.binalimed.com/) as the exclusive distributor and representative in the Middle East. The agreement signed in October 2007, allows BAMS to promote, market and distribute all ITSIBIO’s products and services in the Middle East. Clients in Middle East can now place orders through BAMS. Please visit http://www.itsibio.com/index_intop.htm to see products now available to customers in the Middle East through BAMS.

May, 2007
ITSIBIO enters the Indian market by signing an exclusive agreement with SR Biosytem of New Delhi. Under the agreement signed May 2007, SR Biosytem will promote, market and distribute all ITSIBIO’s line of products, accessories and services in India. All orders in the Indian sub-continent should now be placed through SR Biosystem.

April, 2007
ITSI signs an exclusive agreement with Separation Scientific (SA) (PTY) Ltd, of South Africa. Under the agreement that is effective from April 2007, Separation Scientific will promote, market and distribute all ITSIBIO’s products and services in the South Africa and other neighboring countries. Clients in Southern Africa should now place orders through Separation Scientific (SA) (PTY).

December 5 , 2006
Pennsylvania Governor Rendell announces the investment of $500,000 to enable ITSI to expand its research facility and operations.
Read the official press release on the PA PowerPort website.
Read the Tribune-Democrat feature article on Itsibio.
Download the Tribune-Democrat feature article (with photo) on Itsibio.
Download the invitation to the groundbreaking of Itsibio's new facility.


Architect's rendering of new ITSI research facility
(Click to enlarge)



September 28, 2006
ITSI representative invited to speak at the “South African Bio2Biz International Biotechnology Conference”, Durban, South Africa. A paper titled “From Genomics and Proteomics to Bio-Business” presented.

September 12, 2006
ITSI representative invited to speak at the International Symposium on “Inflammation: An Underlying Factor in Several Diseases”, Ibadan, Nigeria. A paper titled “Role of Proteomics in Inflammation Research” presented as a keynote lecture.

September 7, 2006
ITSI signs a collaboration agreement with the Advancement Center, College of Medicine, University of Nigeria. Under this agreement ITSI will work with the College of Medicine to develop integrated biomedical research programs and a biorepository to support cancer and complex disease research.

August 15, 2006
ITSI signs an exclusive Representative and Distributorship agreement with InterSciences Inc., Markham Ontario, Canada. Under this agreement, InterSciences will promote, market and distribute the ITSIPREP™ line of products and easy-to-use kits for protein isolation, protein fractionation, protein precipitation, albumin removal and protein assay in Canada.

June 2006
Dr Munir O. Azeez (Col.) of the Nigerian Army Medical Corps (NAMC) joins ITSI for six months advanced biomedical research training, as part of the training and collaboration agreement between ITSI and NAMC. Dr Azeez is interested in applying advanced proteomic technologies to study tissue from patients diagnosed with temporo-mandibular joint disease.

May 2006
ITSI signs an exclusive distribution agreement with Funakoshi Japan. Funakoshi will promote, market and sell the ITSIPREP™ line of products in Japan.

www.funakoshi.co.jp

April 2006
ITSI signs a non-exclusive Sales Representative Agreement with Grace Scientific LLC, Clarksburg, MD, USA. Grace Scientific will promote, market and sell ITSI’s services, especially 2D-DIGE and 2D-Image analysis services and all the ITSIPREP™ line of products in the Maryland, Washington DC and Virginia area.

March 2006
ITSI signs an exclusive Representative and Distributorship agreement with Rainbow Biotechnology Co., Taipei, Taiwan. Rainbow will promote, market and distribute the ITSIPREP™ line of products including optimized and easy-to-use kits for protein isolation, protein fractionation, protein precipitation, albumin removal and protein assay.

www.rainbowbiotech.com.tw

February 1 2006
Itsi-Biosciences has moved to a new, larger location. Images of our new facility and additional information will available online shortly. Please see the Contact page for our new address.

January 2006
ITSI appoints Syngenic Biotecnologia Ltda., Sao Paolo Brazil as the exclusive distributor of the ITSIPREP™ line of products in Brazil. The agreement, which was signed in October 2005, covers all the optimized and easy-to-use kits for protein isolation, protein fractionation, protein precipitation, albumin removal and protein assay.

November 24 2005
ITSI-Biosciences President and CSO Richard Somiari Ph.D. is prominently featured in the 11/24/05 issue of Nature. Learn more...

September 14 2005
Itsibio represented at GE Healthcare 2D-DIGE Users Group meeting in Nashville, TN. Presents paper "Application of 2D-DIGE technology for the analysis of clinical specimens."

Download the 2D-DIGE Users Group meeting agenda in .pdf format

September 9 2005
Robin L. Fisher, Director Asia & Europe, International Business Development, PA DCED, Mr. Donald M. Bonk, International Trade Manager, SAPDC and Ms. Sushama A Kanetkar, Director, PA Trade Representative Office in India, and Supriya, Trade & Investment Advisor, PA Trade Office India visit Itsibio corporate headquarters/laboratory to discuss export opportunities and entry into the Indian market.

September 8 2005
Itsibio invited to exhibit products at the Cambria County Chamber of Commerce Small Business Expo in Ebensburg, PA

August 31 2005
Itsibio and Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil sign agreement to explore business opportunities of mutual interest involving proteomics, clinical research/trials, tissue repository development and management.

ITSIBIO representative met with Prof. Carlos Menke and staff of Hospital de Clinicas de Porto Alegre
in Porto Alegre, Brazil on the 16th of June, 2005.

August 12 2005
Itsibio, Applied Isotope Technologies and MountainTop Technologies sign agreement to explore business opportunities of mutual interest involving proteomics.



August 9 2005
Itsibio and Lampire Biological Laboratories, Pipersville, PA sign a three year collaboration and teaming agreement covering antibody production, bioreagent development and proteomics.

August 5 2005
Itsibio signs a distribution agreement with Biomedical Marketing Associates. BMA will market and distribute ITSI’s proteomics products including protein isolation, fractionation and assay kits in 5 states: Michigan, Ohio, Kentucky, West Virginia and Western Pennsylvania.

David H. Fyock, Matt Pamuku, Prof. H.M. (Skip) Kingston, Ph.D., and Dr Steve Anyanruoh, MD with Richard Somaiari, Ph.D. at Itsibio.

July 22 2005

David H. Fyock, Chairman/CEO MountainTop Technologies Inc., Matt Pamuku, President, Applied Isotope Technologies, Inc., Prof. HM (Skip) Kingston, PhD, Duquesne University and Dr. Steve Ayanruoh, MD, Chairman, Ruskat Medical Equipment Corp and Applied Medical Technologies, visit Itsibio to discuss collaboration and teaming agreement.

Stephen C. Metzger, Director Business Lending Services, SAPDC tours Itsibio core laboratory.

July 15 2005

Stephen C. Metzger, Director Business Lending Services of Southern Allegheny Planning & Development Commission, Altoona, PA visits itsibio to discuss funding opportunities and support. SAPDC is supporting itsibio’s effort to export bioanalytical reagents produced in Johnstown, PA to Mexico and Brazil, and to access funds through the Small Business First loan program.

D. Brian Krier (L) and Sherry A. Davidson (C), with Susan Saltys (R) Office Manger, Itsibio

July 14 2005

D. Brian Krier (Director Business Development) and Sherry A. Davidson (Account Manager) both of The Ben Franklin Transformation Services Network, Altoona/University Park, PA visit Itsibio. Ben Franklin Technology Partners has been helping Itsibio since June of 2005 to strategize and transform our overall operations to become more efficient and competitive, both nationally and globally.

Ed Huttenhower, Director, SBDC/Center for Global Competitiveness, St Francis University, visits Itsibio.

July 12 2005

Ed Huttenhower, Director, Small Business Development Center (SBDC)/Center for Global Competitiveness, St Francis University, Loretto, PA visits Itsibio. SBDC is helping Itsibio enter foreign markets, prepare targeted marketing materials and screen foreign companies interested in distribution of Itsibio’s protein isolation and protein assay kits in Mexico and Brazil.

Prof F.A.A. Adeniyi, Steve Russell, Richard Somiari and Denise Papcunik (foreground) of Itsibio

July 11 2005

Prof. Francis A.A. Adeniyi, Dean, Faculty of Basic Medical Sciences and Ag. Director, Institute for Advanced Medical Research & Training (IMRAT), University of Ibadan, Ibadan, Nigeria visits itsi-Biosciences to discuss collaboration in the areas of biomedical research, bioanalytical support, tissue banking and data center development.

July 8 2005

Ciphergen Biosystems ProteinChip System Series 4000

Itsibio acquires ProteinChip System Series 4000 Enterprise Edition Surface Enhanced Laser Desorbed Ionization – Time of Flight (SELDI-Tof) from Ciphergen Biosystems as part of an emerging collaboration between Itsibio and Ciphergen. The system, which is the best for analysis of serum, plasma, urine and saliva will support internal biomarker discovery programs and will enable Itsibio to provide contract biomarker discovery services to academia and pharmaceutical industries.

July 7 2005

Itsibio representatives visit NCI-Frederick, Frederick MD. Present seminar “Integrating emerging high throughput technologies for complex disease research”

July 6 2005

Itsibio representatives visit GE Healthcare, Piscataway NJ. Meet with Andy Bertera, Head of Marketing, Gene & Protein Discovery.

June 20 2005

Itsibio attends Bio 2005, meets with potential partners from around the world.

June 17 2005

Itsibio representative visits Hospital das Clinicas de Porto Alegre, Universidade Federal do Rio Grande Sul, Porto Alegre, Brazil. Presents seminar “Advances in Tissue Banking & Biomedical Research” and meets with Prof Dr. Carlos Menke and top faculty members to discuss partnership.

DCED, SAPDC and PA Mexican Trade Rep. Visit Itsibio

April 19 2005

Mr. Joseph Burke, Director, Americas, So. Africa, Mid. East & Oceania Grp., PA DCED, Mr. Donald M. Bonk, International Trade Manager, SAPDC and Ms. Silvia Alonso, Senior Trade Specialist for PA in Mexico visit itsibio corporate headquarters/laboratory.

April 13 2005

Itsibio attends American Society of Breast Disease (ASBD) annual meeting (April 13-16 2005) in Las Vegas, NV. Itsibio representative serves on the Outreach and special populations committee and is a member of the Expert working group on risk assessment of the ASBD.

March 22 2005

Itsibio representative visits University of Nigeria, Nsukka, Nigeria and presents seminar “Emerging high throughput technologies and complex disease research” Meets with Director, University Resource Foundation, Provost, University of Nigeria Teaching Hospital, Chief Medical Director, University of Nigeria Teaching Hospital and other senior faculty and university administrators to discuss partnership between both organizations.

March 19 2005

Itsibio representative visits the Institute of Advanced Medical Research & Training, University of Ibadan, Nigeria and University College Hospital, Ibadan, Nigeria. Presents a seminar “Advances in High throughput Biomedical Research & Personalized Medicine”. Meets with Prof E. Bababunmi, Prof. Francis AA Adeniyi and Prof. Idowu Yinka and other senior faculty members to discuss partnership between both organizations.

March 18 2005

Itsibio representative attends the launching of the Nigerian Army Medical Corps/School (NAMC/S) “rollback” malaria program. Meets with the Honorable Minister of State for defense Dr. Roland Oritsejafor, Lt. Gen ML Agwai (Chief of Army Staff) and Maj. Gen B. E. Abang (Commandant NAMC/S).

March 4 2005

Itsibio representative visits and presents a seminar” Application of emerging high throughput technologies in complex disease research” at the College of Pharmacy, University of Houston, TX. Meets with Dean Sunny Ohia and senior faculty.

February 02 2005

Itsibio and Asterand Inc. sign collaboration agreement.

January 3 2005

Itsibio formally opens ultra-modern laboratory for genomics and proteomics research and provision of bioanalytical services.